Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
Santi Suryani(Siliwangi University), Richard B. Lock(Cancer Institute of New South Wales), Luke Jones(University College Dublin), Anthony Letai(Dana-Farber Cancer Institute), Viktoras Frimantas(University Children's Hospital Zurich), Malcolm A. Smith(National Cancer Institute), Elise Tonna(Children's Cancer Institute Australia), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Peter J. Houghton(The University of Texas at San Antonio Health Science Center), Tríona Ní Chonghaile(Royal College of Surgeons in Ireland), Chintanu Sarmah(Children's Cancer Institute Australia), Kathryn Evans(Women's & Children's Health Research Institute), Hernán Carol(Children's Cancer Institute Australia), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 0
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934